Sign in
CompletedNo phase

Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan

Key facts

Who runs it
PATH
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
200 people enrolled
Started
1 Jul 2024
Ended
15 Dec 2024
Type of study
Observational, 3 groups
Treatments tested
  • Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)
Record updated
31 July 2025

Who can take part

Age
3 months to 15 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Aged 3 months to 15 years; Presents for care at 1 of 9tertiary hospitals participating in the study; Potential PID+ (Case): Child is identified by HCW to have >2 Jeffrey Model warning signs of PID. [Note: Upon immunology panel testing, this group will be separated into three categories: PID-, PID+, and PID+/PAD+ meaning they have 1 of 5 relevant primary antibody deficiencies (PAD+)]; PID-(Control): Child is identified (by snowball sampling) as being in good health, and having the same age (within 12 months) as another child who produced a PID+ result; Caregiver consents to participate in the study and provides informed consent. If their children are 10 years of age or older, that child must also give assent

Who cannot take part

  • Aged less than 3 months or greater than 15 years of age; Caregiver does not consent to participate, or child >10years does not give assent to participate; Having received IVIG in the past 90 days

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Case-control diagnostic accuracy study with 130 potential pediatric PID+ (primary immunodeficiency) patients, and 100 age-matched, healthy controls (PID-). The potential PID+ participants will be recruited prospectively through 9 hospitals in Sindh and Punjab states or contacted via the PID surveillance registry developed by AKU Hospital's Polio Excretion in PID study to identify children with primary antibody deficiency (PAD+: a type of PID+); healthy, age-matched PID-participants will be recruited by snowball sampling. At the point of care, health care workers (HCWs) will collect capillary blood samples (0.1mL) to run the PID rapid screening test and reader on potential PID+ participants (identified by exhibiting >2 of the Jeffrey Modell warning signs) and healthy, age-matched controls. All pediatric study participants will be sent to the hospital lab to have a confirmatory immunology panel (see 4.4.1 Diagnosing PID for the battery of tests) run on a serum/plasma sample to confirm their PID diagnosis (PID+/PAD-, PID+/PAD+, PID-); a 1.5uL aliquot of serum/plasma will simultaneously be used to run a PID rapid screening test by a laboratory technician (LT). HCWs and LTs will be blinded to true PID status. Blood and serum PID rapid screening test results will be compared to the confirmatory immunology panel to determine diagnostic accuracy. All clinical management of study participants will follow the standard of care for PID in Pakistan and will be based upon the immunology panel result. The HCWs and LTs administering the tests will be trained prior to the diagnostic accuracy test (see Objectives below) and will provide feedback on the tool post-training and post-use to assess usability, acceptability, and feasibility of integrating the test and digital reader into tertiary hospitals for the purpose of improved national PID surveillance, improved PID patient care, and polio eradication in Pakistan.

The 3 groups in the trial

  • Pediatric PID patients (prospective)

    Prospective, age-matched, healthy patients

    Treatment: Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)

  • Pediatric PID patients (recontacted from registry)

    Treatment: Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)

  • Prospective, age-matched, healthy patients

    Treatment: Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
31 July 2025